Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Adaptive Radiotherapy: a Phase II Study (HELP Trial)

NCT07005882 is registered in ClinicalTrials.gov with Azienda Ospedaliero-Universitaria Careggi as lead sponsor.

NCT NCT07005882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07005882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Adaptive Radiotherapy: a Phase II Study (HELP Trial)
Lead sponsor
Azienda Ospedaliero-Universitaria Careggi
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2025
Completion date
March 1, 2028
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer early stage breast cancer (stage 1-3), breast cancer patients, hr+/her2- breast cancer, radiation therapy